Federated Hermes
TARS icon

Federated Hermes’s Tarsus Pharmaceuticals TARS Stock Holding History

Federated Hermes’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1M Buy
65,096
+16,002
+33% +$1.02M 0.01% 892
2026
Q1 		$3.44M Sell
49,094
-195
-0.4% -$13.6K 0.01% 866
2025
Q4 		$4.04M Buy
49,289
+34,057
+224% +$2.54M 0.01% 829
2025
Q3 		$905K Sell
15,232
-39,789
-72% -$1.96M ﹤0.01% 1173
2025
Q2 		$2.23M Buy
55,021
+339
+0.6% +$15.3K ﹤0.01% 915
2025
Q1 		$2.81M Sell
54,682
-23,032
-30% -$1.14M 0.01% 856
2024
Q4 		$4.3M Buy
+77,714
New +$3.53M 0.01% 750
2024
Q3 		– Sell
-26,483
Closed -$720K – 2160
2024
Q2 		$720K Buy
26,483
+11,018
+71% +$370K ﹤0.01% 1207
2024
Q1 		$562K Buy
+15,465
New +$455K ﹤0.01% 1300

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Federated Hermes's TARS Position: Q2 2026 in Review

Federated Hermes increased its Tarsus Pharmaceuticals (TARS) stake by 33% in Q2 2026, buying an estimated $1.02M and bringing the position to 65,096 shares worth $4.1M. The position accounts for 0.01% of the portfolio, ranked #892.

Federated Hermes first reported a position in TARS in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.3M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Federated Hermes held 65,096 shares of Tarsus Pharmaceuticals worth $4.1M as of Q2 2026.
  • Federated Hermes bought 16,002 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
  • Tarsus Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #892 holding.
  • Federated Hermes first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Federated Hermes's Tarsus Pharmaceuticals position peaked at $4.3M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.